Garraway: After 10 mos; 1/2 the cases at least 6 cores. Able to get multiple cfDNA. All for mBrCa. n=94 #MAP16
10:45am September 23rd 2016 via Hootsuite
Garraway: Some samples to genomic and transcriptome; 1 to CLIA; others to single-cell analyses #MAP16
10:44am September 23rd 2016 via Hootsuite
Garraway: Shows busy slide of their workflow - serial tissue or blood biopsies. Punches, multiple cores, or fluid including blood #MAP16
10:43am September 23rd 2016 via Hootsuite
Garraway: Mutational load correlates to clinical benefit; but by itself, could not distinguish between responders/non-resp #MAP16
10:42am September 23rd 2016 via Hootsuite
Garraway: CDK inhib in br ca: CDKN2A dels, CCND1 ampl, not predictive. 'Molecular determinants of response not clearly understood' #MAP16
10:41am September 23rd 2016 via Hootsuite
Garraway: With a long tail: will the % of pts to benefit too small? Is the implied framework too narrow? #MAP16
10:40am September 23rd 2016 via Hootsuite
Garraway: ERCC2 shows up in other cancer types, where platinum Rx not thought about before #MAP16
10:39am September 23rd 2016 via Hootsuite
Garraway: Thus a subset could be ID'd of bladder ca, sensitive to cisplatin. 100% response rate just published (JAMA) #MAP16
10:38am September 23rd 2016 via Hootsuite
Garraway: Shows long-tail diagram from this '14 ref https://t.co/tdkFJHtj7C In bladder: one gene common: ERCC2 in responders #MAP16
Garraway: The 'basket trial' (1-gene, 1-drug) 'is insufficient'. Knowledge of resist. mech incomplete; rational combinations uncommon #MAP16
10:35am September 23rd 2016 via Hootsuite
Garraway: Monitor target over time: rational deployment, 'real-time optimization' of combination Rx for durable disease control #MAP16
10:34am September 23rd 2016 via Hootsuite
Garraway: Combination Rx - 'index' dependencies, immunologic vulnerabilities, prevalent resistance mechanisms #MAP16
10:33am September 23rd 2016 via Hootsuite
Garraway: One anchor: genetic/molecular stratification. Somatic genetics - about 90% of effort. 'But not sufficient' - immuno? #MAP16
10:32am September 23rd 2016 via Hootsuite
Garraway: 11K pts enrolled for enrolling, KBs, clinical trial options, targeted Rx. But ;what might success look like?' #MAP16
10:31am September 23rd 2016 via Hootsuite
Garraway: Now 137-gene, to 700-gene (called OncoPanel) '12. From Proof of Concept, to Development to Clinical implementation #MAP16
10:30am September 23rd 2016 via Hootsuite
Garraway: 'We started with what seems now what should belong in a museum, genotyping by Mass-Spec' ('07 'OncoMap') #MAP16
10:29am September 23rd 2016 via Hootsuite
Garraway: Starts with figure from '13 review https://t.co/HYnuiObPLu Schematic of Patient, 'omic profiling etc. #MAP16
10:28am September 23rd 2016 via Hootsuite
Levi Garraway (Dana-Farber, Boston MA) New Frontiers in Cancer Precision Medicine #MAP16
10:26am September 23rd 2016 via Hootsuite
Hadrup: Barcoding individual MHC complexes, can sort, amplify, and detect '16 Nature Biotech ref https://t.co/V6CJ4ncChk #MAP16
10:08am September 23rd 2016 via Hootsuite
Hadrup: Single-staining of MHC multimers/flow cytometry dates back to Altman 1996. Now use NGS for Ag-responsive T-cells #MAP16
10:07am September 23rd 2016 via Hootsuite
Hadrup: Shows PFS curves, and involvement of immune variation. Their tool - MuPeXi, neo-epitope prediction. https://t.co/zHuSQwqDvI #MAP16
10:06am September 23rd 2016 via Hootsuite
Hadrup: Immune surveillance involves TCR and CD8 on T-cells; MHC-I on cancer cell; mutated MHC can hide cancer antigen #MAP16
10:04am September 23rd 2016 via Hootsuite
Sine Reker Hadrup (Univ Denmark, Copenhagen, Denmark) Integrating cancer genomics with immune phenotyping #MAP16
10:02am September 23rd 2016 via Hootsuite
Lambin: Radiomics publication describing technique: '12 ref https://t.co/FReog6mxcr #MAP16
9:55am September 23rd 2016 via Hootsuite
Lambi: Used CT contrast that clusters very well with patient outcome data. Showed K-M curves for NSCLC and Head-and-Neck ca's #MAP16
9:53am September 23rd 2016 via Hootsuite
Philippe Lambin (Maastricht, Netherlands): Molecular radio-oncology #MAP16 Can quantitative information be extracted from imaging data?
9:45am September 23rd 2016 via Hootsuite
AZ: Shows PFS data from Oxnard '16 ref https://t.co/X0lbObBn4X Plasma is pending US approval #MAP16
8:36am September 23rd 2016 via Hootsuite
AZ: Shows summary results from these two ctDNA T790M studies https://t.co/AsBbz6LOri https://t.co/LGIufOP4q8 #MAP16
8:34am September 23rd 2016 via Hootsuite
AZ: Only 2.5y from discovery to approval, needed a T790M, Roche-developed cobas assay. #MAP16
8:29am September 23rd 2016 via Hootsuite
AZ: Structure-based design, led to osimertinib. Covalent target Cys797, mutant-selective profile #MAP16
8:24am September 23rd 2016 via Hootsuite
AZ: 60% of TKI resist is T790M; 2nd gen irreversible EGFR inhib then developed (afatinib, dacomitinib). Effectiveness limited #MAP16
8:23am September 23rd 2016 via Hootsuite
AstraZeneca talk (name?) '95 Gefitinib (IRESSA) theh first EGFR TKI' high response to Exon 19, L858R mutations #MAP16
8:19am September 23rd 2016 via Hootsuite
Lord: '13 Nature Med ref https://t.co/iJ7WNqLd9C With PARPi, secondary resist clones can be targeted (Wee1) #MAP16
8:13am September 23rd 2016 via Hootsuite
Lord: Lays out the synthetic lethality paradigm; from observation of drug resistance via a partner #MAP16
8:11am September 23rd 2016 via Hootsuite
Lord: Dev of PARP inh - potent, small-molecule, selectively targeting defective BRCA1/2 https://t.co/AIdmV5Fv6R KuDOS now AZ #MAP16
8:09am September 23rd 2016 via Hootsuite
Lord: a 'holy trinity': the biomarker, its penetrance, mol mechanism; heterogeneity, plasticity, evol; and optimal combinations #MAP16
8:07am September 23rd 2016 via Hootsuite
Lord (ICR UK) at AstraZeneca-sponsored luncheon: '10 BMC Ref https://t.co/UOWQUz99TH ~750 entities, 250 genes, 1% of the genome #MAP16
8:05am September 23rd 2016 via Hootsuite
Singh: Concludes w/Globe and Mail - In Canada, hockey is to sport as stem cells is to science https://t.co/3MLeRSSnuc #MAP16
7:51am September 23rd 2016 via Hootsuite
Singh: (Patients, after relapse, are often palliated, no re-examination of the mutations.) Found similar char's in spinal mets #MAP16
7:42am September 23rd 2016 via Hootsuite
Singh: Treat mice with radiation, Rx; mice have MRD and recur. GFP-labelled cells can be re-harvested, interrogated for met mutations #MAP16
7:41am September 23rd 2016 via Hootsuite
Singh: Targeting Bmi1 w/ PTC Therapeutics; showed data on promise of this approach. MB - sampled only once. Moving to NOD-SCID mice #MAP16
7:39am September 23rd 2016 via Hootsuite
Singh: Stem cells - is it Dorian Gray or Benjamin Button? '09 ref https://t.co/2MZUe5X8IG Impt in type 3 MB. Bmi1 gene reg by Sonic #MAP16
7:30am September 23rd 2016 via Hootsuite
Singh: The 4 subtypes published '12 ref https://t.co/yqnfJtrc8x Shh signaling: drives development, and disregulated, drives MB #MAP16
7:27am September 23rd 2016 via Hootsuite
Singh: Hisopathological subtypes 'are of minimal prognostic utility'; different groups characterize them, published '12 #MAP16
7:25am September 23rd 2016 via Hootsuite
Singh: Cushing, Bailey in the '20's. From 50% to now 80% 5y survivorship for std-risk pts. But survivors have neuro damage #MAP16
7:23am September 23rd 2016 via Hootsuite
Singh: One pt died at 15mo, another alive 8y later. But appeared identical. Cancer is like a river 'one cannot step twice' in it #MAP16
7:22am September 23rd 2016 via Hootsuite
Singh: Introduces herself as a neurosurgeon, using medulloblastoma. Starts w/2 childhood cases, most common ped brain tumor #MAP16
7:20am September 23rd 2016 via Hootsuite
Sheila Singh (McMaster Univ Ontario Canada) Therapeutic targeting of childhood medulloblastoma - strategies for blocking recurrence #MAP16
7:19am September 23rd 2016 via Hootsuite
Attard: Presents data from this '15 STM ref https://t.co/hZrLixTrRZ Poster here at #MAP16 develops a ddPCR assay for AR
7:14am September 23rd 2016 via Hootsuite
Attard: Showed results of wt AR vs mutant AR (L702H) over treatment; AR alleles don't acquire CNAs. https://t.co/atikTX0Rg3 #MAP16
7:13am September 23rd 2016 via Hootsuite
